Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan

Anish Patel, Chief Operating Officer of Enliven Therapeutics, sold shares of common stock between July 12 and July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, sold shares of the company's common stock.
• The sales occurred on July 12, July 15, and July 16, 2024.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 29, 2023.
• On July 12, 17,475 shares were sold at a weighted average price of $25.0698.
• On July 15, 30,978 shares were sold at a weighted average price of $25.0513.
• On July 16, 1,547 shares were sold at a weighted average price of $25.0111.
• Following these transactions, Patel directly owns 344,027 shares and indirectly owns 376,552 shares through The Patel / Dong Family Trust Dated August 24 2017, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's prospects.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan allows insiders to sell shares over a period of time without being accused of trading on non-public information. The market will likely interpret this sale in the context of the company's overall performance and future prospects.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates